0.35亿“变脸”竟击垮上市公司？南华生物应主动回购救市！

Group 1 - The core issue is the sudden shift in South China Biological's profit forecast from "expected profit" to "expected loss," leading to a significant drop in stock price and market value [1] - The company reported a reduction in sales revenue by 0.14 billion and an unexpected increase in bad debt provisions by 0.21 billion, totaling a financial adjustment of 0.35 billion [1] - The company's internal control deficiencies and disclosure violations are identified as the root causes of this crisis, resulting in substantial losses for thousands of investors [1] Group 2 - Prior to the profit warning, South China Biological announced a plan to invest 300 million in wealth management, which now appears contradictory given the financial turmoil [2] - This juxtaposition highlights the management's negligence towards shareholder interests, focusing instead on personal financial gains [2] - The management's short-sighted actions have raised doubts about the company's future and its commitment to shareholder value [2] Group 3 - The company is urged to take immediate actions, including suspending the wealth management plan and reallocating those funds for share buybacks to restore market confidence [3] - Management is encouraged to increase their shareholdings to demonstrate commitment and responsibility towards shareholders [3] - A thorough investigation into the disclosure violations is recommended to rebuild trust with investors [3] Group 4 - The incident underscores the importance of maintaining integrity in the A-share market, as such drastic profit changes should not jeopardize a listed company's status [3] - Share buybacks are suggested as a direct and effective measure to stabilize stock prices and enhance the company's market image [3] - Taking decisive actions is crucial for South China Biological to regain investor confidence and ensure its survival in the capital market [3]